Diagnosis of HER2 protein overexpression in patients with breast cancer in Brazil

被引：0
|
作者：
Muranaka, A. H. [1 ]
机构：
[1] Prod Roche Quim & Farmaceut SA, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)70181-9
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A54 / A54
页数：1
相关论文
共 50 条
  • [31] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
    Sasagu Kurozumi
    Mary Padilla
    Masafumi Kurosumi
    Hiroshi Matsumoto
    Kenichi Inoue
    Jun Horiguchi
    Izumi Takeyoshi
    Tetsunari Oyama
    Jim Ranger-Moore
    D. Craig Allred
    Eslie Dennis
    Hiroaki Nitta
    Breast Cancer Research and Treatment, 2016, 158 : 99 - 111
  • [32] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
    Kurozumi, Sasagu
    Padilla, Mary
    Kurosumi, Masafumi
    Matsumoto, Hiroshi
    Inoue, Kenichi
    Horiguchi, Jun
    Takeyoshi, Izumi
    Oyama, Tetsunari
    Ranger-Moore, Jim
    Allred, D. Craig
    Dennis, Eslie
    Nitta, Hiroaki
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 158 (01) : 99 - 111
  • [33] Lapatinib in the treatment of brain metastases in patients with breast cancer with overexpression or amplification of the HER2 gene
    Duchnowska, Renata
    ONCOLOGY IN CLINICAL PRACTICE, 2011, 7 : D6 - D9
  • [34] Protein kinase cα determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification
    Magnifico, Alessandra
    Albano, Luisa
    Campaner, Stefano
    Campiglio, Manuela
    Pilotti, Silvana
    Menard, Sylvie
    Tagliabue, Elda
    CANCER RESEARCH, 2007, 67 (11) : 5308 - 5317
  • [35] HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
    Hou, Yanjun
    Nitta, Hiroaki
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147 (01) : 89 - 95
  • [36] In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer
    Melanie Spears
    Karen J. Taylor
    Alison F. Munro
    Carrie A. Cunningham
    Elizabeth A. Mallon
    Chris J. Twelves
    David A. Cameron
    Jeremy Thomas
    John M. S. Bartlett
    Breast Cancer Research and Treatment, 2012, 132 : 463 - 470
  • [37] Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
    Chen, Zhaoxu
    Jia, Huiqing
    Zhang, Huina
    Chen, Lifang
    Zhao, Peng
    Zhao, Jing
    Fu, Guangming
    Xing, Xiaoming
    Li, Yujun
    Wang, Chengqin
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (02) : 313 - 323
  • [38] Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
    Zhaoxu Chen
    Huiqing Jia
    Huina Zhang
    Lifang Chen
    Peng Zhao
    Jing Zhao
    Guangming Fu
    Xiaoming Xing
    Yujun Li
    Chengqin Wang
    Breast Cancer Research and Treatment, 2023, 202 : 313 - 323
  • [39] Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis
    Yuefeng Wang
    Julia Y. S. Tsang
    Yongmei Cui
    Ji Cui
    Ying Lin
    Songli Zhao
    Patrick T. W. Law
    Sai Yin Cheung
    Enders K. O. Ng
    Gary M. K. Tse
    Zunfu Ke
    Scientific Reports, 7
  • [40] Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis
    Wang, Yuefeng
    Tsang, Julia Y. S.
    Cui, Yongmei
    Cui, Ji
    Lin, Ying
    Zhao, Songli
    Law, Patrick T. W.
    Cheung, Sai Yin
    Ng, Enders K. O.
    Tse, Gary M. K.
    Ke, Zunfu
    SCIENTIFIC REPORTS, 2017, 7
12345